MannKind (MNKD) Scheduled to Post Quarterly Earnings on Wednesday

MannKind (NASDAQ:MNKD) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. The company had revenue of $58.47 million for the quarter, compared to the consensus estimate of $52.36 million. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Trading Up 0.2 %

Shares of MannKind stock traded up $0.01 on Tuesday, hitting $4.41. The company had a trading volume of 244,619 shares, compared to its average volume of 2,844,145. MannKind has a 52 week low of $3.17 and a 52 week high of $5.75. The business has a 50-day simple moving average of $4.43 and a 200-day simple moving average of $3.92.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $6.50 price objective on shares of MannKind in a research note on Friday, March 15th. Wedbush reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of MannKind in a research note on Wednesday, February 28th.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.